Qiagen N.V. (QGEN) vs Revvity (RVTY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Revvity (RVTY) has outperformed Qiagen N.V. (QGEN) over the past year, gaining 65.8% versus a loss of 6.8%. Over five years, RVTY leads with a -10.4% price change compared with -16.4% for QGEN. Revvity is the larger company by market cap ($17.26 billion vs $9.32 billion), about 1.9 times the size, while Qiagen N.V. is growing revenue faster (+5.7% vs +3.7%).
On valuation, Qiagen N.V. trades at a lower forward P/E (17.3x vs 26.3x for Revvity). Qiagen N.V. offers the higher dividend yield (0.80% vs 0.18%). Qiagen N.V. converts more of its revenue into profit, with a net margin of 20.3% versus 8.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | QGEN | RVTY |
|---|---|---|
| Share price | $45.15 | $154.64 |
| Market cap | $9.32B | $17.26B |
| 1-day change | +1.38% | +1.63% |
| YTD return | -0.98% | +57.27% |
| 1-year return | -6.76% | +65.81% |
| 5-year return | -16.44% | -10.40% |
| P/E ratio (TTM) | 22.92 | 73.99 |
| Forward P/E | 17.28 | 26.26 |
| EPS (TTM) | $1.97 | $2.09 |
| Dividend yield | 0.80% | 0.18% |
| Annual dividend | $0.363 | $0.28 |
| Revenue (latest FY) | $2.09B | $2.86B |
| Revenue growth (YoY) | +5.65% | +3.67% |
| Net income (latest FY) | $424.88M | $241.20M |
| Gross margin | 62.18% | — |
| Operating margin | 22.29% | 12.49% |
| Net margin | 20.33% | 8.45% |
| 52-week high | $57.82 | $166.25 |
| 52-week low | $32.53 | $81.22 |
| Distance from 52-week high | -21.92% | -6.98% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +4.71% | -12.14% |
| Average volume | 2.58M | 1.79M |
| Shares outstanding | 206.50M | 111.59M |
| Employees | 5,500 | 11,000 |
| Sector | Health Care | Industrials |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RVTY has outperformed QGEN by 72.6 percentage points over the past year.
- Revvity trades at a higher earnings multiple (74.0x vs 22.9x trailing P/E).
- Qiagen N.V. is more profitable, keeping 20.3 cents of every revenue dollar as net income versus 8.4 cents for Revvity.
- The two companies sit in different sectors: Qiagen N.V. in Health Care and Revvity in Industrials.
About Qiagen N.V.
QGEN stock →Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5,500 employees
About Revvity
RVTY stock →Revvity, Inc. provides health sciences solutions, technologies, and services.
Industrials · Biotechnology: Laboratory Analytical Instruments · 11,000 employees
QGEN vs RVTY FAQ
Which is bigger, Qiagen N.V. or Revvity?
Revvity (RVTY) is larger, with a market capitalization of $17.26B compared with $9.32B for Qiagen N.V. (QGEN).
Which stock has performed better over the past year, QGEN or RVTY?
RVTY returned +65.81% over the past 12 months, compared with -6.76% for QGEN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, QGEN or RVTY?
QGEN has the lower trailing P/E at 22.9, versus 74.0 for RVTY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Qiagen N.V. or Revvity?
Qiagen N.V. has the higher yield at 0.80%, compared with 0.18% for Revvity.
Are Qiagen N.V. and Revvity in the same industry?
No. Qiagen N.V. is in the Health Care sector, while Revvity is in Industrials.